MARKET

CTMX

CTMX

CytomX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.93
-0.47
-6.35%
Opening 15:00 09/21 EDT
OPEN
7.21
PREV CLOSE
7.40
HIGH
7.21
LOW
6.85
VOLUME
280.32K
TURNOVER
--
52 WEEK HIGH
15.44
52 WEEK LOW
3.595
MARKET CAP
320.11M
P/E (TTM)
-5.0393
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced that on September
GlobeNewswire · 3d ago
SPAQ, EROS, CALA and AXTA among after-hours movers
Gainers: [[BRY]] +13.1%. [[LWAY]] +7.1%. [[CTMX]] +7%. [[SPAQ]] +6.7%. [[CALA]] +4.4%.Losers: [[GDS]] -4.5%. [[GRAF]] -3.4%. [[AXTA]] -3.2%. [[BHLB]] -2.3%. [[EROS]] -2%.
Seekingalpha · 09/11 21:41
CytomX Therapeutics to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology platform, announced today
GlobeNewswire · 09/02 13:00
What Type Of Shareholders Make Up CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Share Registry?
The big shareholder groups in CytomX Therapeutics, Inc. (NASDAQ:CTMX) have power over the company. Large companies...
Simply Wall St. · 08/24 14:23
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/08 07:55
CytomX EPS misses by $0.83, misses on revenue
CytomX (NASDAQ:CTMX): Q2 GAAP EPS of -$0.34 misses by $0.83. Revenue of $16.61M (+84.4% Y/Y) misses by $36.38M. Shares -1.6%. Press Release
seekingalpha · 08/07 01:29
CytomX Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update
Company to Host a Conference Call Today, August 6, 2020, at 5:30 p.m. ET / 2:30 p.m. PTSOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneeri
GlobeNewswire · 08/06 20:15
CytomX Therapeutics to Participate in the 2020 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therape
GlobeNewswire · 08/04 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTMX stock price target is 13.17 with a high estimate of 18.00 and a low estimate of 8.50.
EPS
Institutional Holdings
Institutions: 189
Institutional Holdings: 40.34M
% Owned: 87.32%
Shares Outstanding: 46.19M
TypeInstitutionsShares
Increased
47
5.52M
New
46
-381.98K
Decreased
38
3.47M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.86%
Pharmaceuticals & Medical Research
-3.26%
Key Executives
Chairman/President/Chief Executive Officer/Director
Sean McCarthy
Chief Financial Officer/Senior Vice President
Carlos Campoy
Senior Vice President
Leslie Robbins
Executive Vice President
Amy Peterson
Senior Vice President/Chief Scientific Officer
W. Michael Kavanaugh
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Lloyd Rowland
Senior Vice President
Nick Galli
Vice President
Jason Braun
Senior Vice President
Alison Hannah
Lead Director/Independent Director
Matthew Young
Vice President
Glenn Michelson
Independent Director
Charles Fuchs
Independent Director
Halley Gilbert
Independent Director
Frederick Gluck
Independent Director
Elaine Jones
Independent Director
James Meyers
Independent Director
John Scarlett
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More

Analyst Price Target

The average CTMX stock price target is 13.17 with a high estimate of 18.00 and a low estimate of 8.50.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of CytomX Therapeutics Inc stock information, including NASDAQ:CTMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTMX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTMX stock methods without spending real money on the virtual paper trading platform.